Fractyl Health Inc. Commo... (GUTS)
1.82
0.03 (1.68%)
At close: Jan 14, 2025, 3:59 PM
undefined% (undefined)
| Bid | 1.82 |
| Market Cap | 87.54M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.58 |
| PE Ratio (ttm) | -1.15 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.84 |
| Volume | 20,148 |
| Avg. Volume (20D) | 374,900 |
| Open | 1.82 |
| Previous Close | 1.79 |
| Day's Range | 1.82 - 1.83 |
| 52-Week Range | 1.74 - 14.50 |
| Beta | undefined |
About GUTS
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform ...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 122
Stock Exchange NASDAQ
Ticker Symbol GUTS
Website https://fractyl.com
Analyst Forecast
According to 2 analyst ratings, the average rating for GUTS stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 889.01% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
+16.46%
Fractyl Health shares are trading higher after the...
Unlock content with
Pro Subscription
9 months ago ·
Source
-9.53%
Fractyl Health shares are trading lower amid possible volatility. The company yesterday initially spiked after it announced FDA IDE approval for the Revita Remain-1 pivotal study and then rebounded after reporting Q4 financial results.
